Current guidelines for leprosy treatment;Prise en charge médicale actuelle de la maladie de Hansen

Bulletin de la Societe de Pathologie Exotique

Volumn 96, Issue 5, 2004, Pages 357-361

  Flageul, B ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Antibacillary multidrug therapy; Leprosy; Reactional state

Indexed keywords

CLARITHROMYCIN; LEPROSTATIC AGENT; MINOCYCLINE; OFLOXACIN;

BRAIN INJURY; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG POTENCY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; IMMUNE RESPONSE; IMMUNITY; LEPROSY; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; RELAPSE; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

DRUG THERAPY, COMBINATION; ERYTHEMA NODOSUM; HUMANS; LEPROSTATIC AGENTS; LEPROSY; LEPROSY, LEPROMATOUS; PRACTICE GUIDELINES;

EID: 1442314605     PISSN: 00379085     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. de CARSALADE GY, WALLACH D, SPINDLER E, PENNEC J, COTTENOT F & FLAGEUL B - Daily multi-drug therapy for leprosy: Results of a fourteen years experience. Int J Lepr, 1997, 65, 37-44.
2. 2b. de CARSALADE GY, ACHIRAFI A & FLAGEUL B - Pentoxifylline for erythema nodosum leprosum. J Dermatol, 2003, 30, 64-68.
3. FLAGEUL B - Maladie de Hansen - Encycl Méd Chir Dermatologie. Editions Scientifiques et Médicales Elsevier SAS, Paris, 2001, 98-370-A-10, 19p.
4. FLAGEUL B - Enquête épidémiologique sur lèpre en France métropolitaine, de 1995 à 1998. Ann Dermatol Vénéréol, 2001, 128, 17-20.
5. FLAGEUL B, VIGNON-PENNAMEN MD, WALLACH D & COTTENOT C - Les réactions de réversion tardives au cours de la lèpre. Acta Leprol, 1991, 7, 331-334.
6. JI B - Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev, 2001, 72, 3-7.
7. MOREIRA AL & KAPLAN G - Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL. Int J Lepr, 1998, 66, 61-65.
8. ORG. MOND. SANTÉ - WHO STUDY GROUP - Chemotherapy of leprosy for control programmes. Sér rapp techn no 675. OMS, 1982, Genève.
9. ORG. MOND. SANTÉ - WHO EXPERT COMMITTEE ON LEPROSY - Sér rapp techn no 768. OMS, 1988, Genève.
10. ORG. MOND. SANTÉ - WHO STUDY GROUP - Chemotherapy of leprosy for control programmes. Sér rapp techn no 847. OMS, 1994, Genève.
11. ORG. MOND. SANTÉ - WHO ACTION PROGRAMME FOR ELIMINATION OF LEPROSY - A guide to eliminating leprosy as a public health problem. WHO/LEP/98.1, 1998, Genève.
12. ORG. MOND. SANTÉ - WHO EXPERT COMMITTEE ON LEPROSY -Seventh Report. Sér rapp tec no 874. OMS, 1998, Genève.
13. ORG. MOND. SANTÉ - WHO MODEL PRESCRIBING INFORMATION -Drugs used in leprosy. WHO/DMP/DS/98.1, 1998, Genève.
14. ORG. MOND. SANTÉ - WHO LEPROSY ELIMINATION GROUP -Guide to eliminate leprosy as a public health problem. WHO/CDS/CPE/CEE/2000.4, 2000, Genève.
15. PFALTGRAFF RE - The control of neuritis in leprosy with clofazimine. Int J Lepr, 1972, 40, 392-398.
16. Report of the International Leprosy Association Technical Forum, 25-28 February 2002. Paris, France. Lepr Rev, 2002, 73, Suplt June.
17. RIDLEY DS & JOPLING WH - Classification of leprosy according to immunity: a five group system. Int J Lepr, 1966, 34, 255-273.
18. SCHULZ EJ - Forty-four months' experience in the treatment of leprosy with clofazimine. Lepr Rev, 1972, 42, 178-187.